Navigation Links
NUCRYST Receives Deficiency Notice from NASDAQ
Date:9/18/2009

PRINCETON, NJ, Sept. 18 /PRNewswire-FirstCall/ - NUCRYST Pharmaceuticals, a developer and manufacturer of medical products that fight infection and inflammation, today announced that on September 15, 2009 it received notice from the Nasdaq Stock Market that it no longer complies with Nasdaq Marketplace Rule 5550(a)(2) because, for the previous 30 consecutive business days, the bid price of its common stock had closed below the minimum requirement of $1.00 per share. Receipt of this notification has no immediate effect on the NASDAQ listing of the Company's common shares.

In accordance with Marketplace Rule 5810(c)(3)(A), the Company has until March 15, 2010 to regain compliance, which requires a closing bid price of the Company's common stock at or above $1.00 per share for a minimum of 10 consecutive business days. In the event the Company does not regain compliance within this period, Nasdaq will issue a written notification that the Company's shares are subject to delisting. If the Company is not deemed in compliance prior to March 15, 2010, but demonstrates that it meets all applicable standards for initial listing on the Nasdaq Capital Market (except the bid price requirement) on such date, it will be afforded an additional 180 day compliance period.

NUCRYST is currently evaluating its alternatives to resolve the listing deficiency.

About NUCRYST Pharmaceuticals Corp.

NUCRYST Pharmaceuticals Corp. (NASDAQ: NCST; TSX: NCS) develops, manufactures and commercializes medical products that fight infection and inflammation using SILCRYST(TM), its patented atomically disordered nanocrystalline silver technology. NUCRYST licensed world-wide rights for SILCRYST(TM) wound care coating products to Smith Nephew plc, which markets these products in over 30 countries under their Acticoat(TM) tra
'/>"/>

SOURCE NUCRYST Pharmaceuticals Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. European Launch of Acticoat(TM) Flex with NUCRYSTs Nanocrystalline Silver Technology Announced by Smith Nephew
2. Conference Call Advisory - NUCRYST Pharmaceuticals Corp. Conference Call to Discuss 2009 Second Quarter Results
3. NUCRYST announces 2009 first quarter financial results
4. Conference Call Advisory - NUCRYST Pharmaceuticals Corp. Conference Call to Discuss 2009 First Quarter Results
5. NUCRYST Announces Fourth Quarter and Year End 2008 Financial Results
6. NUCRYST Approves $0.80 Per Share Cash Distribution to Shareholders
7. NUCRYST appoints interim CEO
8. NUCRYST Pharmaceuticals appoints a new director
9. NUCRYST Receives Requisition to Call a Special Meeting of Shareholders From Majority Shareholder
10. The Westaim Corporation requisitions meeting of shareholders of NUCRYST Pharmaceuticals to return capital to NUCRYST shareholders
11. NUCRYST Receives Deficiency Notice from NASDAQ
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/18/2014)... neuroscientists have made a discovery that turns 160 years ... insulating material long known to be essential for the ... cells, is not as ubiquitous as thought, according to ... the Harvard Stem Cell Institute (HSCI) and the University,s ... with Professor Jeff Lichtman, of Harvard,s Department of Molecular ...
(Date:4/18/2014)... did it make you feel? According to psychologists, remembering ... as how sad you were or how embarrassed you ... can,t stop thinking about it. , When these ... the memories, rather than how you felt, is a ... effects of these memories, a new study suggests. , ...
(Date:4/18/2014)... Two Simon Fraser University psychologists have made a ... treatment of attention-deficit disorders. , This discovery opens ... may hinder or suppress a specific brain activity ... prevent distraction. , The Journal of Neuroscience ... discovery by John McDonald, an associate professor of ...
(Date:4/18/2014)... is available in French . ... surgical practice and regenerative medicine. A team led by ... (CNRS/ESPCI Paris Tech) and Didier Letourneur from the Laboratoire ... has just demonstrated that the principle of adhesion by ... to repair soft-tissue organs and tissues. This easy-to-use gluing ...
(Date:4/17/2014)... of chronic inflammation in benign prostate tissue was ... this association was found even in those with ... study published in Cancer Epidemiology, Biomarkers & ... for Cancer Research. , An analysis of prostate ... placebo arm of the Prostate Cancer Prevention Trial ...
Breaking Medicine News(10 mins):Health News:Finding turns neuroanatomy on its head 2Health News:Finding turns neuroanatomy on its head 3Health News:New study suggests a better way to deal with bad memories 2Health News:New study suggests a better way to deal with bad memories 3Health News:Scientists discover brain's anti-distraction system 2Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3
... is known for being the sole manufacturer of the stem ... to go public//. The company is slated to sell out ... with the Securities and Exchange Commission. ,Stem cells have ... raging about what this science can really offer. Controversy has ...
... mothers are demanding that they be allowed to breastfeed babies ... weight behind this proposal saying that 'women should feel confident ... Kidney's Private Member's Bill has called for a breastfeeding law ... was passed in March. In a survey by the NCT, ...
... parents of junior athletes seem to have a negative impact ... in the British Journal of Sports Medicine. ,The ... junior tennis coaches in the US, which looked at the ... The coaches had all spent an average of 17 years ...
... Minister Tony Clement has said that anti-virals will be made ... This was part of Canada’s preparation efforts to combat a ... everyone who is ill to receive treatment. A strategy is ... will get them." ,Several programs have been initiated to ...
... thrombosis (DVT) occurs when people sit in the same position ... blood causing clots in the legs//. The condition can be ... lungs, causing a pulmonary embolism. DVT which has long been ... up with a solution called flip seats which give passengers ...
... there is no evidence to blame phones towers, the chief ... that chance// is a more likely explanation for the Melbourne ... any other environmental exposure. . ,Professor Coates explained that ... there is usually no cause every time they happen though ...
Cached Medicine News:Health News:Parents of Junior Athletes do More Harm than Good 2
(Date:1/14/2014)... Ore. , Jan. 14, 2014 /PRNewswire-iReach/ -- Acumed,s ... a targeting guide with accompanying instrumentation to place and ... adjunct to the soft tissue (e.g. ligament) repair or ... tissue repair heals. (Photo: http://photos.prnewswire.com/prnh/20140114/MN45636 ) ...
(Date:1/14/2014)... , Jan. 14, 2014   NuAire , a manufacturer of ergonomically ... with Hitachi Koki of Japan ... North America . NuAire will utilize its network of ... Canada to offer assistance in application use, ...
(Date:1/14/2014)... , Jan. 14, 2014   Oligomerix, Inc. , a ... therapeutics for Alzheimer,s disease (AD) and related neurodegenerative disorders, ... Valhalla, NY as of January ... space at New York Medical College. Oligomerix, ...
Breaking Medicine Technology:Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 2Acumed introduces the Scapho-Lunate Inter Carpal (SLIC) Screw System 3NuAire announces sales and service of Hitachi Koki centrifuges in North America 2Oligomerix Relocates Corporate Headquarters and Secures Additional Laboratory Space from New York Medical College 2
... BURLINGTON, Mass., Dec. 7, 2010 ... cardiovascular diagnostic imaging technologies, today announced the publication of ... association of stent thrombosis with lipid core plaque as ... is the first and only FDA-approved system to provide ...
... 2010 Cymetrix, a leader in providing healthcare ... announced an alliance with Siemens Healthcare for financial ... partnership, Cymetrix will assist in the transition of ... systems to Siemens Soarian®. Cymetrix,s system conversion solution ...
Cached Medicine Technology:InfraReDx Announces Publication of a Case Report in Circulation Highlighting Novel Clinical Finding with LipiScan™ Coronary Imaging System 2Cymetrix Forms Alliance With Siemens Healthcare for System Conversion Support 2
Intended for the quantitative in vitro enzymatic determination of JDL-Cholesterol in human serum or plasma. Two point reaction. Wavelength: 600 nm. Linearity: 1 to 150 mg/dL (0.03 mmol/L to 3.89 mmol...
Ready to use liquid single reagent for automated chemistry analyzers. Linearity to 1000 mmol/L...
The new ProteomeX Workstation enables the rapid set up, execution and analysis of multidimensional LC/MS methods, providing you with the best possible technique to characterize your complex proteomic...
Intended for the quantitative determination of triglycerides in serum or plasma. Reaction: endpoint. Wavelength: 520 nm. Linearity: 1000 mg/dL (11.3 mmol/L). Single vial, dry powder reagent....
Medicine Products: